Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0087 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0087 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0077 | 0.7709 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0087 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0087 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0054 | 0.2291 | 0.2291 |
Chlamydia trachomatis | sulfite reductase | 0.0054 | 0.2291 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0087 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0077 | 0.7709 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0087 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0087 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0087 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0087 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0087 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0087 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0087 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0087 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0087 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0087 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0087 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0087 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0087 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0087 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0087 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0087 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0087 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | = 0.1 uM | Tested in vitro for cytotoxicity against human tumor cell line OVCAR8 (ovarian). | ChEMBL. | 10714502 |
GI50 (functional) | = 0.1 uM | Tested in vitro for cytotoxicity against human tumor cell line OVCAR8 (ovarian). | ChEMBL. | 10714502 |
GI50 (functional) | = 0.2 uM | Tested in vitro for cytotoxicity against human tumor cell line MCF-7/ADR (breast) | ChEMBL. | 10714502 |
GI50 (functional) | = 0.2 uM | Tested in vitro for cytotoxicity against human tumor cell line MCF-7/ADR (breast) | ChEMBL. | 10714502 |
GI50 (functional) | = 0.55 uM | Tested in vitro for cytotoxicity against human tumor cell line DU-145 (prostate) | ChEMBL. | 10714502 |
GI50 (functional) | = 0.55 uM | Tested in vitro for cytotoxicity against human tumor cell line DU-145 (prostate) | ChEMBL. | 10714502 |
GI50 (functional) | = 0.6 uM | Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal). | ChEMBL. | 10714502 |
GI50 (functional) | = 0.6 uM | Tested in vitro for cytotoxicity against human tumor cell line UACC 62 (melanoma) | ChEMBL. | 10714502 |
GI50 (functional) | = 0.6 uM | Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal). | ChEMBL. | 10714502 |
GI50 (functional) | = 0.6 uM | Tested in vitro for cytotoxicity against human tumor cell line UACC 62 (melanoma) | ChEMBL. | 10714502 |
GI50 (functional) | = 20 uM | Tested in vitro for cytotoxicity against human tumor cell line HOP62 (lung) | ChEMBL. | 10714502 |
GI50 (functional) | = 20 uM | Tested in vitro for cytotoxicity against human tumor cell line HOP62 (lung) | ChEMBL. | 10714502 |
GI50 (functional) | > 30 uM | Tested in vitro for cytotoxicity against human tumor cell line SF-268 (CNS). | ChEMBL. | 10714502 |
GI50 (functional) | > 30 uM | Tested in vitro for cytotoxicity against human tumor cell line SF-268 (CNS). | ChEMBL. | 10714502 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.